Marijuana (Cannabis) as medicine

Journal of Cannabis Therapeutics

Volumn 1, Issue 1, 2001, Pages 5-27

  Hollister, Leo E ^a  

^a University of Texas Harris County Psychiatric Center   (United States)

Author keywords

Anorexia; Asthma; Cannabis; Dronabinol; Glaucoma; Insomnia; Marijuana; Pain; Seizures; Spasticity; THC; Vomiting

Indexed keywords

EID: 85019531242     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v01n01_02     Document Type: Article

References (79)

1. AMA Council on Scientific Affairs. 1980. Marihuana reconsidered:Pulmonary risks and therapeutic potentials. Conn Med, 44:521–523.
2. AMA Council on Scientific Affairs. 1981. Marijuana. Its health hazards and therapeutic potentials. J Amer Med Assoc, 248:1823–1827.
3. Agurell, S., Halldin, H., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., and Hollister, L. E., 1986. Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacological Rev, 38:21–43.
4. Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellamen, P., and Yangco, B., 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage, 10:89–97.
5. Bhargava, H. N., 1978. Potential therapeutic application of naturally occurring and synthetic cannabinoids. General Pharmacol, 9:195–213.
6. Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N., Seipp, C., Barofsky, Z., Simon, P., and Rosenberg, S., 1979. Delta-9-tetrahydrocannabinol as antiemetic in cancer patients receiving high-dose methotrexate; a prospective, randomized evaluation. Ann Int Med, 91:819–824.
7. Clifford, D. B., 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals Neurol, 13(6):669–671.
8. Consroe, P. F., Wood, G. C., and Buchsbaum, H., 1975. Anticonvulsant effect of marihuana smoking. J Amer Med Assoc, 234:306–307.
9. Consroe, P., Sandyk, R., and Snider, S. R., 1986. Open label evaluation of cannabidiol in dystonic movement disorder. Intern J Neuroscience, 30:277–282.
10. Consroe, P., Musty, R., Rein, J., Tillery, W., and Pertwee, R., 1997. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology, 38(1):44–48.
11. Cooler, P., and Gregg, J. M., 1977. Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans. South Med J, 70:951–954.
12. Cousens, K., and Dimascio, A., 1973. Delta-9-THC as an hypnotic. An experimental study of 3 dose levels. Psychopharmacologia, 33:355–364.
13. Cunha, J. M., Carlini, E. A., Periera, A. E., Ramos, O. L., Pimental, C., Gagliardi, R., Snavito, W. L., Lander, N., and Mechoulam, R., 1980. Chronic administration of cannabi-diol to healthy volunteers and epileptic patients. Pharmacology, 21:175–185.
14. Doblin, R. E., and Kleiman, M. A.R., 1991. Marijuana as antiemetic medicine:A survey of oncologist’s experiences and attitudes. J Clin Oncol,:313–319.
15. Dunn, M., and Davis, R., 1974. The perceived effects of marijuana on spinal cord injured males. Paraplegia, 12(3):175–178.
16. Ekert, H., Waters, K. D., Julik, I. A., Mobina, J., and Lougnnan, P., 1979. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocanna-binol. Med J Aust, 2:657–659.
17. Feigenbaum, J. J., Richmond, S. A., Wiessman, Y., and Mechoulam, R., 1989. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic canna-binoid. European J Pharmacol, 169:159–165.
18. Feinberg, I., Jones, R., Walker, J., Caveness, C., and Floyd, E., 1976. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther, 19:782–794.
19. Foltin, R. W., Brady, J. V., and Fischman, M., 1986. Behavioral analysis of marijuana effect on food intake in normals. Pharmacology Biochemistry Behavior, 25:573–582.
20. Freemon, F. R., 1974. The effect of delta-9-tetrahydrocannabinol on sleep. Psycho-pharmacology, 35:39–44.
21. Frytak, S., Moertel, C., O’Fallon, J., Rubin, J., Creagan, E., O’Nell, M., Schutt, A., and Schwarau, N., 1979. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann Int Med, 91:825–830.
22. Gaoni, Y., and Mechoulam, R., 1964. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc, 86:646–1648.
23. Gilbert, P. E., 1981. A comparison of THC, nantradol, nabilone and morphine on chronic spinal dog. J Clin Pharmacol, 21:311S–319S.
24. Greenberg, H. S., Werness, S. A., Pugh, J. E., Andrus, R. O., Anderson, D. J., and Domino, E. F., 1994. Short-term effects of smoking marihuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharm Ther, 55:324–328.
25. Grinspoon, S., Corcoran, C., Askari, H., Schoenfeld, D., Wolf, L., Burrows, B., Walsh, M., Hayden, D., Parlman, K., Anderson, E., Basgoz, N., and Klibanski, A., 1998. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 129(1):18–26.
26. Hanigan, W. C., Destree, R., and Truong, X. T., 1986. The effect of delta-9-THC on human spasticity. J Amer Soc Clin Pharmacol Therap, 39 Feb.:198
27. Hepler, R. S., and Frank, I. R., 1971. Marihuana smoking and intraocular presssure. J Amer Med Assoc, 217(10):1392
28. Hill, S. Y., Schwin, R., Goodwin, D. W., and Powell, B. J., 1974. Marihuana and pain. J Pharmacol Exp Ther, 188(2):415–418.
29. Himmelsbach, C. K., 1944. Treatment of the morphine-abstinence syndrome with a synthetic cannabis-like compound. Southern M J, 37:26–29.
30. Hollister, L. E., Richards, R. K., and Gillespie, H. K., 1968. Comparison of tetrahydrocannabinol and synhexl in man. Clin Pharmacol Ther, 9:783–791.
31. Hollister, L. E., 1974. Structure activity relationship in man of cannabis constituents and homologues of delta-9-tetrahydrocannabinol. Pharmacology, 11:3–11.
32. Hollister, L. E., 1971. Hunger and appetite after single doses of marihuana, alcohol and dextroamphetamine. Clin Pharmacol Ther, 12:44–49.
33. Hollister, L. E., Gillespie, H. K., Ohlsson, A., Lindgren, J. E., Whalen, A., and Agurell, S., 1981. Do plasma concentrations of delta-9-hydrocannabinol reflect the degree of intoxication. J Clin Pharmacol, 21:171S–177S.
34. Hollister, L. E., 1986. Health aspects of cannabis. Pharmacol Rev, 38(6):2–20.
35. Isbell, H., Gorodetzy, G. W., Jasinski, D., Claussen, V., Spulak, F. V., and Korte, F., 1967. Effects of f_3 delta-trans-tetrahydrocannabinol in man. Psychopharmacologia, 11:184–188.
36. Jain, A. K., Ryan, J. R., McMahon, F. G., and Smith, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol, 21:320S–326S.
37. Kluin-Neleman, J. C., Neleman, F. A., Meuwissen, O. J., and Maes, R. A., 1979. Del-ta-9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy:a double-blind cross-over trial against placebo. Vet Hum Toxicol, 21:338–340.
38. Lane, M., Vogal, C. L., Ferguson, J., Dransow, S., Saiers, J. L., Hamm, J., Slava, K., Wiernik, P. H., Holroyde, C. P., Hammil, S., Sheppard, K., and Plasse, T., 1991. Dronabinol and prochlorperazine in combination for treatment of cancer. J Pain Symptom Manage, 16:352–359.
39. Lichtman, A. H., and Martin, B. R., 1991. Spinal and supraspinal components of canna-binoid-induced antinociception. J Pharmacol Exp Ther, 258:517–523.
40. Loewe, S., 1946. Studies on the pharmacology and acute toxicity of compounds with marijuana activity. J Pharmacol Exper Therap, 88:154–161.
41. Loewe, S., and Goodman, L. S., 1947. Anticonvulsant action of marijuana-active substances. Fed Proc, 6:352
42. Lucas, V. S., Jr. and Laszlo, J., 1980. Delta-9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. J Amer Med Assoc, 243:1241–1243.
43. Malec, J., Harve, R. F., and Cayner, J. J., 1982. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil, 63(3):116–118.
44. Mattes, R. D., Engelman, K., Shaw, L. M., and Elsohly, M. A., 1994. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav, 49:187–195.
45. Maurer, M., Henn, V., Dittrich, A., and Hofmann, A., 1990. Delta-9-Tetrahydrocanna-binol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci, 240(1):1–4.
46. Meinck, H. M., Schonie, P. W., and Conrad, B., 1989. Effect of cannabinoids on spastic-ity and ataxia in multiple sclerosis. J Neurol, 236:120–2.
47. Merritt, J. C., McKinnon, S., Armstrong, J. R., Hatem, G., and Reid, L. A., 1980. Oral delta-9-tetrahydrocannabinol in heterogeneous glaucomas. Ann Ophthamol, 12:947–950.
48. Merritt, J. C., Crawford, W., Alexander, P., Anduze, A., and Gelbart, S., 1980. Effect of marijuana on intraocular and blood pressure in glaucoma. Ophthalmol, 87:222–228.
49. Nahas, G. G., 1973. “The medical use of cannabis”. In Marijuana in Science and in Medicine, Edited by:Nahas, G. G., New York:Raven Press.
50. Nakano, S., Gillespie, H. K., and Hollister, L. E., 1978. A model for evaluation of antianxiety drugs with the use of experimentally-induced stress:Comparison of nabilone and diazepam. Clin Pharmacol Ther, 23:54–62.
51. Neidhart, J., Gagen, M. M., Wilson, H. E., and Young, D. C., 1981. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol, 21:385S–342S.
52. Nelson, K., Walsh, D., Deeter, P., and Sheehan, F., 1994. A phase II study of delta-9-tet-rahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Pal-liat Care, 10:14–18.
53. Nelson, K., and Walsh, D., 1995. Appetite effect of dronabinol. J Clin Oncol, 12:1524–1525.
54. Noyes, R., Brunk, S. T., Avery, D. H., and Canter, A., 1975. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther, 18:84–89.
55. Orr, L. E., McKerran, J. F., and Bloome, B., 1980. Antiemetic effect of tetrahydrocan-nabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Int Med, 140:1411–1433.
56. Parker, C. S., and Wigley, F., 1950. Synthetic cannabis preparations in psychiatry. Synhexyl. J Ment Sc, 96:276–279.
57. Perez-Reyes, M., Wagner, D., Wall, M. E., and Davis, K. H., 1976. “Intravenous administration of cannabinoids and intraocular pressure”. In Pharmacology of Marihuana, Edited by:Braude, M., and Szara, S., 829–832. New York:Raven Press.
58. Petro, D. J., and Ellenberger, C. E., 1989. Treatment of human spasticity with del-ta-9-tetrahydrocannabinol. J Neurol, 236:120–122.
59. Pivik, R. T., Zarcone, V., Dement, W. C., and Hollister, L. E., 1972. Delta-9-tetrahydro-cannabinol and synhexyl; effects on human sleep patterns. Clin Pharmacol Ther, 13:426–435.
60. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., and Wadleigh, R. G., 1991. Recent clinical experiences with dronabinol. Pharmacol Biochemistry Behavior, 40:695–700.
61. Pond, D. A., 1948. Psychological effects in depressive patients of the marijuana homologue, synhexyl. Neurol Neurosurg Psychiatr, 11:271–279.
62. Raft, D., Gregg, J., Ghia, J., and Harris, L., 1977. Effect of intravenous tetrahydrocan-nabinoids on experimental and surgical pain. Clin Pharmacol Ther, 21:26–33.
63. Regelson, W., Butler, J. R., Schulz, J., Kirk, T., Peek, L., Green, M. L., and Zalis, M. O., 1976. “Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite stimulating agent in advanced cancer patients”. In Pharmacology of Marijuana, Edited by:Braude, M. C., and Szara, S., Vol. 2, New York:Raven Press.
64. Sallan, S. E., Zinberg, N. E., and Frei, E., 1975. Antiemetic effect of delta-9-tetrahydro-cannabinol in patients receiving cancer chemotherapy. N Engl J Med, 293:795–797.
65. Sallan, S. E., Cronin, C., Zelen, M., and Ainberg, N. E., 1980. Antiemetics in patients receiving chemotherapy for cancer:a randomized comparison of delta-9-tetrahy-drocannabinol and prochlorperazine. N Engl J Med, 302:135–138.
66. Schwartz, R. H., 1994. Marijuana as an antiemetic drug:How useful is it? Opinions from clinical oncologists. J Addictive Dis, 13(1):53–65.
67. Stockings, G. T., 1947. New euphoriant for depressive mental states. Brit M J, 1:918–922.
68. Tashkin, D. P., Shapiro, B. J., and Lee, V. E., 1975. Effects of a smoked marihuana in experimentally induced asthma. Am Rev Respir Dis, 112:377–385.
69. Thompson, L. J., and Proctor, R. C., 1953. Continued use of pyrahexyl in treatment of alcoholic and drug withdrawal conditions. North Carolina M J, 14:520–523.
70. Turkanis, S. A., Cely, W., Olson, D. M., and Karler, R., 1974. Anticonvulsant properties of cannabidiol. Res Commun Chem Pathol Pharm, 8:231–246.
71. Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, O., Sarna, G., and Jamison, K., 1982. Cannabis and cancer chemotherapy:a condition of oral delta-9-tetrahy-drocannabinol and prochlorperazine. Cancer, 50:636–645.
72. Ungerleider, J. T., and Andrysiak, T., 1985. Therapeutic issues of marijuana and THC (tetrahydrocannabinol). Int J Addictions, 20(5):691–699.
73. Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Ellison, G. W., and Myers, L. W., 1987. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in Alcohol & Substance Abuse, 7(1):39–50.
74. Vachon, L., Fitzgerald, N. X., Solliday, N. H., Gould, L. A., and Gaensler, E. A., 1973. Bronchial dynamics and respiratory-center sensitivity in normal subjects. N Eng J Med, 288:985–989.
75. Vinciguerra, V., Moore, T., and Brennan, E., 1988. Inhalation marijuana as an anti-emetic for cancer chemotherapy. New York State J Med, 88:525–528.
76. Voth, E. A., and Schwartz, R. H., 1997. Medicinal Applications of delta-9-tetrahydro-cannabinol and marijuana. Ann Int Med, 126:791–798.
77. Wada, J. A., Sato, M., and Corcoran, M. E., 1973. Antiepileptic properties of delta-9-tet-rahydrocannabinol. Exp Neurol, 39:157–165.
78. Williams, S. J., Hartley, J. P.R., and Graham, J. D.P., 1972. Bronchodilator effect of delta-9-tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax, 331:720–723.
79. Zinberg, N. E., 1979. On cannabis and health. J Psychedel Drugs, 11:135–144.